Clinical trials: sponsored by Kyowa Kirin Co., Ltd.
Type 2 Diabetes
A Study of OPC-262 in Patients With Type 2 Diabetes
The purpose of this clinical study is to evaluate the safety and efficacy of OPC-262 5 mg in patients with type 2 diabetes by repeated administration orally for 52 weeks.
- Trial name
- NCT01046318
- Testing
- OPC-262
- Where
- 3 sites in Japan
- Volunteers
- 100 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Diabetes, Type 2
A Phase 3 Study of OPC-262 in Patients With Type 2 Diabetes
The purpose of this study is to investigate the safety of OPC-262 administered orally in combination with another oral antihyperglycemic agent
- Trial name
- NCT01193179
- Testing
- OPC-262
- Where
- 4 sites in Japan
- Volunteers
- 450 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Diabetes, Type 2
Along-term Study of OPC-262 in Patients With Type 2 Diabetes
The purpose of this clinical study is to evaluate the safety of OPC-262 (2.5 mg and 5 mg) in patients with type 2 diabetes by long-term administration orally for 52 weeks and to evaluate the efficacy of OPC-262
- Trial name
- NCT01634282
- Testing
- OPC-262
- Where
- 7 sites in Japan
- Volunteers
- 222 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Diabetes Type 2
A Study of OPC-262 in Patients With Type 2 Diabetes
The purpose of this clinical study is to evaluate the superiority of the efficacy of OPC-262 (2.5 mg, and 5 mg) to placebo in patients with type 2 diabetes after 24 week treatment in a double-blind fashion and to evaluate the…
- Trial name
- NCT00997282
- Testing
- OPC-262 2.5 mg, OPC-262 5 mg
- Where
- 7 sites in Japan
- Volunteers
- 255 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Postherpetic Neuralgia
A Comparative Study of KHK6188
This is a placebo-controlled, double blind, crossover study to evaluate the efficacy and safety of KHK6188 in postherpetic neuralgia when administered orally for 2 weeks.
- Trial name
- NCT01544296
- Testing
- KHK6188
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Moderate to Severe Plaque Psoriasis
A Phase 2 Clinical Study of KHK4827
This study is designed to evaluate the efficacy and safety of KHK4827 in subjects with moderate to severe plaque psoriasis in a randomized, double-blind, placebo-controlled, parallel group study.
- Trial name
- NCT01748539
- Testing
- KHK4827
- Where
- Japan
- Volunteers
- 140 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Solid Tumors
A Study of LY2523355 in Patients With Solid Cancer
The primary objective of this study is to examine a recommended dose for subsequent phase trial(s), by the observation of the safety and toxicity profiles of LY2523355 in patients with advanced and/or metastatic cancer.
- Trial name
- 2523355-001 (NCT01358019)
- Testing
- LY2523355
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Psoriasis
A Clinical Pharmacology of KHK4827 in Healthy Volunteers and Subject With Moderate to Severe Psoriasis
This is a randomized, placebo-controlled, ascending single dose study of KHK4827 to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous or intravenous administration of KHK4827 in healthy male…
- Trial name
- NCT01488201
- Testing
- KHK4827
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Adult T-Cell Leukemia and Lymphoma (ATL), Adult Peripheral T-Cell Lymphoma (PTCL)
Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL
This is a Phase I label dose escalation study of KW-0761 in relapsed patients with CCR4 positive Adult T-Cell Leukemia-Lymphoma (ATL) and Peripheral T-Cell lymphoma (PTCL).
- Trial name
- NCT00355472
- Testing
- KW-0761
- Where
- Japan
- Volunteers
- 16 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Cancer
A Phase 1 Study of ARQ 197 in Patients With Solid Tumors
This is a Phase 1, open label, dose escalation study of ARQ 197 in patients with advanced/recurrent solid tumors. The purpose of this study is to determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197.
- Trial name
- NCT00609921
- Testing
- ARQ197
- Volunteers
- 42 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Anemia
A Double-blind Study of KRN321 for the Treatment of Anemia in Cancer Patients
To compare the effectiveness of KRN321 to placebo in the treatment of anemia in cancer patients receiving multi cycle platinum-containing chemotherapy
- Trial name
- NCT00344409
- Testing
- darbepoetin alfa
- Where
- 7 sites in Japan
- Volunteers
- 200 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Parkinson's Disease
Long-Term Safety Study of KW-6002 (Istradefylline) in Parkinson's Disease Patients
Patients with Parkinson's disease who completed the prior double-blind study 6002-009 are eligible to enter into this long-term study.
- Trial name
- 6002-010 (NCT00957203)
- Testing
- Istradefylline
- Where
- Japan
- Volunteers
- 308 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Anemia
A Dose Finding Study of KRN321(Darbepoetin Alfa) for the Treatment of Anemia in Subjects With Solid Tumor
To assess the clinical effective dose of KRN321 administered with once triweekly schedule.
- Trial name
- NCT00359840
- Testing
- darbepoetin alfa
- Where
- 8 sites in Japan
- Volunteers
- 120 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Pain, Cancer
Clinical Study of KW-2246 in Patients With Cancer Pain
This study is a Phase II open-label study to investigate the recommended conversion ratio (oral morphine dose to KW-2246) when switching oral morphine or oxycodone to KW-2246 in cancer patients.
- Trial name
- NCT00355628
- Testing
- KW-2246 (fentanyl citrate)
- Where
- Japan
- Volunteers
- 40 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Parkinson's Disease
A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
To establish the efficacy of 40 mg/day doses of istradefylline for the change in Unified Parkinson's Disease Rating Scale (UPDRS) part-III (Motor examination) score in patients with Parkinson's disease (PD).
- Trial name
- NCT00250393
- Testing
- Istradefylline (KW-6002)
- Where
- Japan
- Volunteers
- 64 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Parkinson's Disease
A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
The purpose of this study is to establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with advanced Parkinson's…
- Trial name
- NCT00455507
- Testing
- Istradefylline
- Where
- Japan
- Volunteers
- 363 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Parkinson's Disease
Study of KW-6002 (Istradefylline) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
The purpose of this study is to establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with advanced Parkinson's…
- Trial name
- 6002-009 (NCT00955526)
- Testing
- Istradefylline
- Where
- Japan
- Volunteers
- 373 people
- Sponsor
- Kyowa Kirin Co., Ltd.
End Stage Renal Disease, Hyperparathyroidism, Secondary
Mineral and Bone Disorders Outcomes in Stage 5D of Chronic Kidney Disease
The MBD-5D is a prospective observational study with a case-cohort and a cohort design. Eligible patients are receiving hemodialysis and have secondary hyperparathyroidism.
- Trial name
- MBD-5D (NCT00995163)
- Where
- Japan
- Volunteers
- 8,020 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Pain, Cancer
Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.
The purpose of this study is to determine the effectiveness and safety of sublingual fentanyl tablets in relieving breakthrough pain in cancer patients.
- Trial name
- NCT00262678
- Testing
- EN3267
- Where
- United States
- Sponsor
- Kyowa Kirin Co., Ltd.